Provention Bio Inc. (PRVB) Tops Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
Provention Bio Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update
March 19, 2019 4:05 PM EDTOLDWICK, N.J., March 19, 2019 /PRNewswire/ --Â Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2018 and provided a business update.
"During 2018, we made great strides towards the achievement of our strategic goal of... More
